Zejing Pharmaceutical announced that the company's application for the marketing of a new drug for the treatment of active ankylosing spondylitis was recently accepted by the State Drug Administration. This is the third indication for the drug to be marketed as a new drug. The acceptance number is CXHS2600137.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.